Comment: Cochrane review on the topic «Franco JV, Guo Y, Varela LB, et al. Tirzepatide fo...»7 was published in 2025. We chose not to include it in this evidence summary, because the review includes trials where obesity or overweight was not the target of the intervention, and therefore dosage and administration routes in some of the trials differed from those that aim to treat obesity.
| Reference | Study type | Population | Intervention and comparison | Outcomes | Risk of bias |
|---|---|---|---|---|---|
| RCT=randomized controlled trial; SR=systematic review; MA=meta-analysis | |||||
| «Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepa...»1 Jastreboff et al. 2022 (SURMOUNT-1) |
Randomized controlled trial (RCT), parallel-group | 2539 adults with BMI ≥30 or ≥27 + ≥1 weight-related complication, without diabetes. Conducted in nine countries at 119 sites | Tirzepatide 5 mg, 10 mg, or 15 mg weekly vs. placebo. 72-week treatment including 20 week dose escalation period; all groups received standardized lifestyle counseling. | Percent change in body weight, proportions achieving ≥5%, ≥10%, ≥15%, ≥20% weight loss; cardiometabolic markers; adverse events | Low |
| «Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepa...»2 Garvey et al. 2023 (SURMOUNT-2) | Randomized controlled trial (RCT) | 938 adults with obesity or overweight and type 2 diabetes (BMI ≥27 kg/m², HbA1c 7–10%), 7 countries, 77 sites. | Once-weekly tirzepatide 10 mg or 15 mg vs placebo for 72 weeks, with standardized lifestyle counselling. | Percent change in body weight and proportion achieving ≥5% weight loss at week 72; higher weight-loss thresholds, glycaemic control (HbA1c), cardiometabolic markers, adverse events. | low |
| «Jastreboff AM, le Roux CW, Stefanski A, et al. Tir...»3 Jastreboff et al.2024 (SURMOUNT-1) |
RCT (prediabetes subgroup of SURMOUNT-1, long-term) | 1032 adult patients with BMI ≥30 or ≥27 with at least one obesity-related complication and prediabetes. Study sites in multiple countries. | Tirzapatide 5, 10 or 15mg or placebo for 176 weeks, followed by a 17 week off-treatment
period All participants received lifestyle counseling. |
Percent change in body weight at week 176, onset of type II diabetes by week 176/193 | Moderate |
| «Wadden TA, Chao AM, Machineni S, et al. Tirzepatid...»4 Wadden et al. 2023 (SURMOUNT 3-study) |
RCT | 579 adults with body mass index ≥30 or ≥27 kg/m2 and at least one obesity-related complication (excluding diabetes). Conducted in Argentina, Brazil, and USA. |
Patients who achieved ≥5.0% weight reduction after a 12-week intensive lifestyle intervention were randomized to tirzepatide (maximum tolerated dose, 10 or 15 mg weekly) vs. placebo for 72 weeks. |
Percent weight loss from randomization to week 72, proportion achieving ≥5% additional weight loss, cardiometabolic parameters | Low |
| «Aronne LJ, Sattar N, Horn DB, et al. Continued Tre...»5 Aronne et al. 2024 (SURMOUNT-4 trial) |
Randomized controlled trial (RCT), randomized withdrawal design | Adults with BMI ≥30 or ≥27 with at least one weight-related complication, excluding diabetes. Conducted in 70 sites in Argentina, Brazil, Taiwan, and USA. | 36-week open-label tirzepatide treatment followed by 52-week double-blind continuation tirzepatide (n=335, maximum tolerated dose of 10 or 15 mg weekly) vs. placebo (n=335). All participants received lifestyle counseling. | Mean percent change in weight from randomization, proportion maintaining ≥80% of initial weight loss, cardiometabolic parameters, adverse events | Moderate |
| «Packer M, Zile MR, Kramer CM, et al. Tirzepatide f...»6 Packer et al. 2025 | RCT | 732 adult patients, age over 40, with heart failure (NYHA II-IV, ejection fraction
at least 50%) and obesity (BMI ≥30) Study sites were not reported. |
Tirzepatide up to 15 mg subcutaneously once per week or placebo for at least 52 weeks | Primary end points were 1) a composite of adjudicated death from cardiovascular causes or a worsening heart-failure event 2) the change from baseline to 52 weeks in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS) |
Moderate |
| Reference | Comments |
|---|---|
| «Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepa...»1 Jastreboff et al. 2022 | SURMOUNT-1, 86.0% of participants completed the primary trial treatment period (88.4% to 89.8% across the tirzepatide groups and 77.0% in the placebo group) and 81.9% adhered to the treatment or placebo as assigned (83.5% to 85.7% across the tirzepatide groups and 73.6% in the placebo group). |
| «Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepa...»2 Garvey et al. 2023 | (SURMOUNT-2, 859 (92%) participants completed the study (296 [95%], 282 [91%], and 281 [89%] with tirzepatide 10 mg, tirzepatide 15 mg, and placebo, respectively) and 819 [87%] completed the study treatment (283 [91%], 268 [86%], and 268 [85%] with tirzepatide 10 mg, tirzepatide 15 mg, and placebo, respectively. 476 (51%) were female. |
| «Jastreboff AM, le Roux CW, Stefanski A, et al. Tir...»3 Jastreboff et al. 2024 | Long-term follow-up (176 weeks) of the prediabetes subgroup from the SURMOUNT-1 RCT; not an independent RCT. Industry-funded. High drop-out rate (34.4%), characteristics for the drop-outs were not reported. Over 3-year follow-up, no major new safety concerns identified. After 176 weeks up until 193 weeks when the treatment was ceased, the intervention group started to gain weight. Eight of these subjects developed type II diabetes in this short time frame. |
| «Wadden TA, Chao AM, Machineni S, et al. Tirzepatid...»4 Wadden et al. 2023 | Of the 806 participants enrolled to the study, 579 (71.8%) achieved ≥5% weight reduction after a 12-week intensive lifestyle intervention. These participants were randomized to either tirzepatide maximum tolerated dose (n=287) or placebo (n=292). The distribution of participants receiving 10 mg vs. 15 mg tirzepatide was not reported; outcomes were analyzed in a pooled maximum tolerated dose group. Of the 579 randomized participants, 479 (82.7%) completed the study (87.8% on tirzepatide maximum tolerated dose, 10-15 mg) and 77.7% on placebo) and 429 (74.1%) completed the study on treatment (78.7% on tirzepatide MTD and 69.5% on placebo). Industry-funded. |
| «Aronne LJ, Sattar N, Horn DB, et al. Continued Tre...»5 Aronne et al. 2024 | SURMOUNT-4 trial, Of 952 screened, 783 entered the 36-week open-label tirzepatide lead-in; 113 discontinued (mainly due to adverse events or withdrawal). Of the 670 randomized (92.7% achieved a maximum tolerated dose of 15 mg and 7.3% achieved a maximum tolerated dose of 10 mg) 335 continued tirzepatide and 335 switched to placebo. Overall, 600 (89.6%) completed the study, and 575 (85.8%) did so while on treatment. The placebo group had higher discontinued rates (25 vs. 45). Most participants were women (70.6%) and white (80.1 %). Randomization was stratified by country, sex, maximum tolerated dose of tirzepatide, and percent weight reduction at week 36 (<10% vs ≥10%). Those who tolerated initial treatment with tirzepatide may represent a subgroup of general population. Prior exposure to tirzepatide and the subjective nature of its effects could have compromised blinding functionally, leading to bias. Industry-funded. |
| «Packer M, Zile MR, Kramer CM, et al. Tirzepatide f...»6 Packer et al. 2025 | A total of 1494 patients were initially screened, although the recruitment setting and procedures were not reported. Of these, only 731 were subsequently randomized. The study was industry-funded. The primary end points were revised one year before the end of the trial. The changes were discussed with the FDA and investigators remained blinded to the data before and during the changes. |
Results
| Reference | Number of studies and number of patients (I/C) | Follow-up time | Weight loss in kg:s mean, % I | Weight loss in kg:s mean, % C | Estimated difference tirzepatide vs. placebo, % (95% CI) |
|---|---|---|---|---|---|
| Level of evidence: high I= intervention; C=comparison; CI=confidence interval |
|||||
| «Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepa...»1 Jastreboff et al. 2022 | 1 study, I: n = 630 (5 mg), 636 (10 mg), 630 (15 mg); C: n = 643 |
72 weeks | 5 mg: –15.0% (95% CI –15.9 to –14.2) |
Placebo: –3.1% (95% CI –4.3 to –1.9) |
5 mg: –11.9 % (95% CI –13.4 to –10.4) |
| 10 mg: –19.5% (95% CI –20.4 to –18.5) |
10 mg: –16.4 % (95% CI –17.9 to –14.8) |
||||
| 15 mg: –20.9% (95% CI –21.8 to –19.9) |
15 mg: –17.8 % (95% CI –19.3 to –16.3) |
||||
| «Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepa...»2 Garvey et al. 2023 | 1 study, I: n = 312 (10 mg), 311 (15 mg); C: n = 315 |
72 weeks | 10 mg: –12.9 kg (-12.8%) |
Placebo: –3.2 kg (-3.2%) |
10 mg: –9.6 %(95% CI –11.1 to –8.1) |
| 15 mg: –14.8kg (-14.7%) |
15 mg: –11.6 % (95% CI –13.0 to –10.1) |
||||
| «Jastreboff AM, le Roux CW, Stefanski A, et al. Tir...»3 Jastreboff et al. 2024 | I=247(5mg), 262 (10 mg), 253 (15 mg), C=270 | 176 weeks | 5 mg: -12.4 kg (-12.3%, 95% CI −14.5 to −10.2%) |
Placebo: - 0.9 kg (-1.3% (95% CI −4.0 to +1.5%) |
5 mg: -11.1% (95% CI, −14.4 to −7.8) |
| 10 mg: -20.0 kg (-18.7% (95% CI −24.1 to −13.4%) |
10 mg −17.5% (95% CI, −23.6 to −11.3) |
||||
| 15 mg: -21.4 kg (-19.7% (95% CI −22.1 to −17.3) |
15 mg -18.4% (95% CI, −22.2 to −14.7 |
||||
| «Wadden TA, Chao AM, Machineni S, et al. Tirzepatid...»4 Wadden et al. 2023 | 1 study, I=287 (10/15 mg) C=292 |
72 weeks | 10/15 mg: -18.4% |
Placebo: +2.5% |
10/15 mg: -20.8% (-23.2 – 18.5) |
| Reference | Number of studies and number of patients (I/C) | Follow-up time | Absolute number of events (%) I | Absolute number of events (%) C | Relative effect (95% CI) |
|---|---|---|---|---|---|
| Level of evidence: high I= intervention; C=comparison; CI=confidence interval, NR=not reported |
|||||
| «Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepa...»1 Jastreboff et al. 2022 | 1 study; I: n = 630 (5 mg), 636 (10 mg), 630 (15 mg); C: n = 643 |
72 weeks | 5 mg ≥5% 85% (82 to 89) ≥10% 68.5 (64.5 to 72.5) ≥15%, 48.0 (43.9 to 52.1) ≥20%, 30.0 (26.4 to 33.6) |
Placebo: ≥5%, 35% (30 to 39) ≥10%, 18.8 (14.9 to 22.7) ≥15%, 8.8 (5.9 to 11.7) ≥20%, 3.1 (1.1 to 5.1) |
NR |
| 10 mg ≥5% 89% (86 to 92) ≥10%, 78.1 (74.4 to 81.7) ≥15%, 66.6 (62.6 to 70.6) ≥20%, 50.1 (46.0 to 54.2) |
|||||
| 15 mg ≥5%, 91% (88 to 94) ≥10%, 83.5 (80.0 to 86.9) ≥15%, 70.6 (66.7 to 74.5) ≥20%, 56.7 (52.6 to 60.8) |
|||||
| «Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepa...»2 Garvey et al. 2023 | 1 study 10 mg: n=312 15 mg: n=311 Placebo: n=315 |
72 weeks | 10 mg: ≥5% 247/312 (79%) ≥10% 189/312 (61%) ≥15% 10 mg: 124/312 (40%) |
Placebo: ≥5% 102/315 (32%) ≥10% 30/315 (9%) ≥15% 8/315 (3%) |
≥5% weight loss 10 mg vs placebo: OR 8·3 (5·6 to 12·3); p<0·0001 15 mg vs placebo: OR 10·5 (6·8 to 16·1); p<0·0001 |
| ≥10% weight loss 10 mg vs placebo: OR 16·1 (9·9 to 26·1); 15 mg vs placebo: OR 19·4 (11·9 to 31·7); |
|||||
| 15 mg: ≥5% 257/311 (83%) ≥10% 15 mg: 202/311 (65%) ≥15% 149/311 (48%) |
≥15% weight loss 10 mg vs placebo: OR 25·2 (12·2 to 52·1); 15 mg vs placebo: OR 36·1 (17·5 to 74·5); |
||||
| «Jastreboff AM, le Roux CW, Stefanski A, et al. Tir...»3 Jastreboff 2024 | I=247(5mg) 262 (10 mg) 253 (15 mg) C=270 | 176 weeks | 5mg: ≥5% n=NR (78%) ≥10%: n=NR, (62%) ≥15%: n=NR, (42%) 10 mg: ≥5% n=NR (85%) ≥10%: n=NR, (75%) ≥15%: n=NR, (61%) 15 mg: ≥5% n=NR (87%) ≥10%: n=NR, (79%) ≥15%: n=NR, (66%) |
Placebo: ≥5% n=NR (29%) ≥10%: n=NR, (15%) ≥15%: n=NR, (8%) |
NR |
| «Wadden TA, Chao AM, Machineni S, et al. Tirzepatid...»4 Wadden et al. 2023 | I=287 (10-15mg, max tolerated dose) C=292 |
72 weeks | 10-15 mg: ≥5% 87.5% ≥10%: 76.7% ≥15%: 65.4% ≥20%: 44.7 % |
Placebo: ≥5%: 16.5 % ≥10%: 8.9% ≥15%: 4.2% ≥20%: 2.2 % |
≥5% OR: 34.6 (19.2–62.6) ≥10% OR: 34.7 (17.6–68.3) ≥15% OR: 48.2 (19.2–121.0) ≥20%: OR 40.4 (12.2-133.8) |
| Reference | Number of studies and number of patients (I/C) | Follow-up time | Weight loss in kg:s mean, (%) I | Weight loss in kg:s mean, (%) C | Estimated difference tirzepatide vs. placebo (95% CI) |
|---|---|---|---|---|---|
| «Aronne LJ, Sattar N, Horn DB, et al. Continued Tre...»5 Aronne et al. 2024 | I =335 Maximum tolerated dose (10 or 15 mg) C=335 |
From randomization week 36 to 88 weeks |
-5,5 % (-6.8 to -4.2) −4.7 kg, (-5.7-3.6), |
+14.0% (12.8- 15.2) +11.1 kg (10.1-12.2), |
-19.4% (-21.2 - 17.7) -15.8 kg (-17.3-14.3) |
| Reference | Number of studies and number of patients (I/C) | Follow-up time | Absolute number of events (%) I | Absolute number of events (%) C | Hazard ratio (95% CI) |
|---|---|---|---|---|---|
| Level of evidence: low. The quality of evidence is downgraded due to study limitations
and imprecision. I= intervention; C=comparison; CI=confidence interval |
|||||
| «Packer M, Zile MR, Kramer CM, et al. Tirzepatide f...»6 Packer 2025 | 364/367 | Median 104 weeks | Composite outcome (death from cardiovascular outcome or worsening of heart failure) 36 (9.9) |
56 (15.3) | 0.62 (0.41-0.95) |
| Death from cardiovascular causes 8 (2.2) |
5 (1.4) | 1.58 (0.52-4.83) | |||
| Worsening heart-failure event 29 (8.0) |
52 (14.2) | 0.54 (0.34-0.85) | |||
| Death from any cause 19 (5.2) |
15 (4.1) | 1.25 (0.63-2.45) | |||